Welcome to our dedicated page for Incyte news (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte stock.
Incyte Corporation (INCY) reports developments for a biopharmaceutical business focused on hematology, oncology, and inflammation and autoimmunity. Recurring updates cover commercial medicines such as Jakafi, Jakafi XR, and Opzelura, regulatory decisions for approved and investigational therapies, and clinical data across blood cancers, graft-versus-host disease, dermatology, and solid tumors.
Company news also includes financial results, product revenue trends, pipeline progress, investor conference participation, executive appointments, equity inducement awards, and international regulatory updates tied to hematology and oncology therapies.
Incyte (Nasdaq: INCY) granted inducement equity awards to 24 new employees under its 2024 Inducement Stock Incentive Plan. The grants, effective August 3, 2026, include RSUs for an aggregate 21,556 shares and stock options for 18,172 shares at an exercise price of $118.43 per share.
According to the company, RSUs vest in four annual 25% tranches, while options have a 10-year term and vest 25% after one year, with the balance vesting in 36 equal monthly installments, all subject to continued service and made in line with Nasdaq Listing Rule 5635(c)(4).
Specialised Therapeutics announced that Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, is now listed on Australia’s Pharmaceutical Benefits Scheme (PBS) from 1 August 2026 for adults with relapsed or refractory follicular lymphoma (R/R FL, Grade 1–3a).
This is the first chemotherapy‑free, dual‑targeted CD19/CD20 immunotherapy regimen reimbursed on the PBS for these patients. The listing follows April 2026 TGA registration via Project Orbis and is enabled through Specialised Therapeutics’ exclusive 2021 distribution agreement with Incyte (NASDAQ: INCY) for Australia, New Zealand and Singapore.
In the Phase 3 inMIND trial, the Minjuvi combination reduced the risk of disease progression, relapse or death by 57% versus placebo plus rituximab and lenalidomide, with median progression‑free survival of 22.4 months vs 13.9 months (HR 0.43; P<0.0001). Safety was described as generally manageable but included high rates of infections and myelosuppression, requiring blood count monitoring and infection vigilance.
Incyte (Nasdaq: INCY) announced that the European Commission has approved Opzelura® (ruxolitinib) cream as the first steroid-free topical JAK inhibitor in the EU for adults with moderate atopic dermatitis whose disease is inadequately managed by, or unsuitable for, topical corticosteroids and topical calcineurin inhibitors.
The approval is based mainly on Phase 3b TRuE‑AD4 data, where Opzelura met both co-primary endpoints at Week 8: higher EASI-75 and IGA Treatment Success versus vehicle. Efficacy was maintained with as-needed dosing through Week 24, with EASI-75 in 84.3% and IGA-TS in 70.6% of patients, marked reductions in affected body surface area, and sustained itch and quality-of-life improvements. According to Incyte, Opzelura was well tolerated over 24 weeks with no serious infections, major cardiovascular events, malignancies or thromboses reported.
Incyte (Nasdaq: INCY) reported second quarter 2026 total revenue of $1.67 billion, up 38% year over year, with total net sales of $1.49 billion, up 40%. Excluding a one-time, non-cash Opzelura® benefit tied to a CMS agreement, total net sales grew 17%.
Jakafi®/Jakafi XR™ net sales were $817 million (+7%), Opzelura net sales $450 million (+173%; or $204 million, +24% excluding the one-time benefit), and the Hematology/Oncology portfolio reached $222 million (+69%). Cash, cash equivalents and marketable securities were $4.5 billion at June 30, 2026.
Incyte raised 2026 guidance for total net sales to $5.13–$5.26 billion, Opzelura to $1.05–$1.10 billion, and Hematology/Oncology to $860–$890 million, and increased GAAP operating expense guidance to $4.915–$4.995 billion, reflecting the $1.25 billion Vega Therapeutics acquisition and an estimated $1.27 billion IPR&D expense in Q3 2026.
Halozyme (Nasdaq: HALO) announced a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology.
According to Halozyme, it will receive an upfront payment from Incyte, plus potential milestone payments and royalties on net sales of medicines using ENHANZE®. Incyte also receives an option to nominate up to two additional targets for use with ENHANZE®.
Incyte (Nasdaq: INCY) will present new clinical data from its oncology portfolio in six sessions at the ESMO Congress 2026, held October 23-27, 2026, in Madrid. Four rapid oral presentations will feature Phase 1 data on INCB161734 (KRAS G12D inhibitor) in advanced/metastatic colorectal cancer and pancreatic ductal adenocarcinoma, INCA33890 (TGFβR2×PD-1 bispecific antibody) in microsatellite stable colorectal cancer, and INCB123667 (CDK2 inhibitor) with bevacizumab in recurrent epithelial ovarian cancer. Two poster presentations will cover final overall survival outcomes from the Phase 3 POD1UM-303/InterAACT-2 study of retifanlimab in first-line advanced squamous anal cancer and the Phase 3 MAESTRA 3 trial of INCB123667 with bevacizumab as first-line maintenance therapy in advanced epithelial ovarian-related cancers.
Incyte (Nasdaq: INCY) reported complete Phase 1/2 multidose data for VGA039 (latarcibart), a Protein S‑targeting investigational monoclonal antibody for von Willebrand disease (VWD), in 16 patients presented at ISTH 2026.
Latarcibart once‑monthly subcutaneous prophylaxis achieved a median 81% reduction in annualized bleeding rate (ABR) across all VWD types and bleed categories. In patients switching from von Willebrand factor (VWF) IV prophylaxis, bleed reductions were 75–100%. Among patients without prior IV prophylaxis but with historical ABR >12, reductions ranged from 46–100%, with 6 of 7 above 73%. VWF‑treated breakthrough bleeds were reduced by about 86%, and 70% of patients with prior VWF‑treated bleeds had none on treatment.
Latarcibart was reported as safe and well tolerated over six doses; three related treatment‑emergent adverse events (two Grade 2 headaches in one patient, one Grade 1 injection site reaction) and one unrelated serious GI bleed occurred. All participants with substantial baseline bleed burden continued into an open‑label extension. A pivotal Phase 3 VIVID‑6 trial in VWD is currently enrolling.
Incyte (Nasdaq: INCY) will release its Q2 2026 financial results on July 28, 2026. The press release is scheduled for 7:00 a.m. ET, followed by a conference call and webcast at 8:00 a.m. ET.
Investors can join via domestic or international dial-in, or access a live webcast with slides on the company’s investor relations website. Phone replay will be available for 30 days, and webcast replay for 90 days.
Incyte (Nasdaq: INCY) completed its acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront, plus up to $750 million in sales milestones. The deal adds VGA039, a Phase 3 investigational monoclonal antibody for von Willebrand disease, to Incyte’s hematology portfolio.
VGA039 has multiple U.S. FDA designations and is being studied as a once‑monthly subcutaneous prophylactic therapy in the global Phase 3 VIVID-6 trial. Incyte expects to record the transaction as a one-time R&D expense in Q3 and full-year 2026 GAAP and non-GAAP results.
Star Therapeutics, a late clinical-stage biotech, will present complete Phase 1/2 multidose data for VGA039 in von Willebrand disease at the ISTH 2026 Congress in Paris (July 11-15, 2026). VGA039, a Protein S-targeting monoclonal antibody in Phase 3 pivotal development, is being studied as a once-monthly subcutaneous prophylactic for all VWD types.
Earlier in June, Incyte (Nasdaq: INCY) agreed to acquire Vega Therapeutics for $1.25 billion upfront plus up to $750 million in sales milestones, adding VGA039 to its hematology portfolio for up to $2.0 billion total consideration.